Form 4 for FTH Faeth Therapeutics, Inc.

Accepted 2023-02-17 00:00:00 ET · period of report 2023-02-15 · accession 0001209191-23-010731 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DM	2023-02-17	2023-02-15	FTH	Celebi John	Pres, CEO, Dir	A - Grant	$0.00	+73.2K	106.0K	+223%	$0
D	2023-02-17	2023-02-15	FTH	Celebi John	Pres, CEO, Dir	A - Grant	$0.00	+90.0K	90.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-02-15	A	A	21,300	$0.00	127,307	D	—	—	(F2) These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date.
2	Common	Common Stock	2023-02-15	A	A	51,893	$0.00	106,007	D	—	—	(F1) These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested.
3	Derivative	Stock Option (Right to Buy)	2023-02-15	A	A	90,000	$0.00	90,000	D	$1.43 · — to 2033-02-14	90,000 Common Stock	(F3) The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.